Milan‑based AAVantgarde closed a $141 million Series B round led by investors including Amgen Ventures to advance gene therapies for inherited retinal diseases. The company said proceeds will accelerate IND‑enabling studies and clinical development for two lead programs targeting inherited blindness. Investors highlighted the addressable ophthalmology market and the opportunity to deploy AAV platform improvements. The financing positions AAVantgarde to push through translational milestones and scale GMP production for ocular trials, where vector design and manufacturing are critical gating factors.